NCT00556049View on ClinicalTrials.gov

Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2014

Conditions
Renal Cell CarcinomaNeoplasm Metastases
Interventions
DRUG

Gemcitabine

Intravenously on days 1 and 8 of each 21-day treatment cycle.

DRUG

Sunitinib

Orally on days 1-14 of each 21-day treatment cycle

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center', Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

lead

Massachusetts General Hospital

OTHER

NCT00556049 - Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter